"If Washington isn ’t careful, we might leave innovation behind"

“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, aVoters for Cures advocate from South Carolina who reminds us what ’s at stake in the broader public policy debate around medical innovation, access and affordability.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development Drug Cost Multiple Sclerosis GoBoldly Source Type: news

Related Links:

AbstractPurpose of ReviewIn this review, current literature on management of neurogenic bladder in patients with multiple sclerosis (MS) is summarized. Topics include a review of MS, a brief overview of general treatment options, the effects of MS may manifest on lower urinary tract symptoms (LUTS), and clinical assessment of these patients. The utility of urodynamic evaluation in this patient population and the use of antibiotic prophylaxis in patients with MS on immunomodulatory medications are reviewed.Recent FindingsUnlike neurogenic bladder in spinal cord patients, lower urinary tract dysfunction in MS patients rarely...
Source: Current Bladder Dysfunction Reports - Category: Urology & Nephrology Source Type: research
FRIDAY, July 12, 2019 -- For patients with severe progressive multiple sclerosis, a standing frame program can increase motor function, according to a study published in the August issue of The Lancet Neurology. Jennifer Freeman, Ph.D., from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
euth SG Abstract Autoimmune diseases of the central nervous system (CNS) like multiple sclerosis (MS) are characterized by inflammation and demyelinated lesions in white and grey matter regions. While inflammation is present at all stages of MS, it is more pronounced in the relapsing forms of the disease, whereas progressive MS (PMS) shows significant neuroaxonal damage and grey and white matter atrophy. Hence, disease-modifying treatments beneficial in patients with relapsing MS have limited success in PMS. BAF312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in PMS....
Source: Cell Research - Category: Cytology Authors: Tags: Neural Regen Res Source Type: research
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: Source Type: podcasts
The objective...
Source: Health and Quality of Life Outcomes - Category: International Medicine & Public Health Authors: Tags: Research Source Type: research
Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-na ïve and pre-treated MS patients who had been prescribed GA for 1 year,...
Source: BMC Neurology - Category: Neurology Authors: Tags: Research article Source Type: research
DiscussionWe explored the efficacy of several MT programs, taking into account the different aspects of application feasibility in the clinical management of MS patients and the future challenges.
Source: Neurological Sciences - Category: Neurology Source Type: research
This article describes a new algorithm for comparing two gait trials recorded with inertial measurement units (IMUs). This algorithm uses a library of step templates extracted from one trial and attempts to detect similar steps in the second trial through a greedy template matching approach. The output of our method is a similarity index (SId) comprised between 0 and 1 that reflects the similarity between the patterns observed in both trials. Results on healthy and multiple sclerosis subjects show that this new comparison tool can be used for both inter-individual comparison and longitudinal follow-up.
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
In this study, we aimed to assess the clinical and cost effectiveness of a home-based, self-managed, standing frame programme.MethodsSUMS was a pragmatic, multicentre, randomised controlled superiority trial of people with progressive multiple sclerosis and severe mobility impairment, undertaken in eight centres from two regions in the UK. The study had assessor-blinded outcome assessments with use of clinician-rated and patient-rated measures at baseline, 20 weeks, and 36 weeks. After baseline assessment, participants were randomised (1:1) by computer-generated assignment to either a standing frame programme plus usual ca...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: August 2019Source: The Lancet Neurology, Volume 18, Issue 8Author(s): Michelle Ploughman
Source: The Lancet Neurology - Category: Neurology Source Type: research
More News: Multiple Sclerosis | Pharmaceuticals